ABSTRACT
Prostate-specific antigen (PSA) screening for prostate cancer remains controversial because it increases overdiagnosis and overtreatment of clinically insignificant tumors. Accounting for genetic determinants of constitutive, non-cancer-related PSA variation has potential to improve screening utility. We discovered 128 genome-wide significant associations (P<5×10-8) in a multi-ancestry meta-analysis of 95,768 men and developed a PSA polygenic score (PGSPSA) that explains 9.61% of constitutive PSA variation. We found that in men of European ancestry, using PGS-adjusted PSA would avoid 31% of negative prostate biopsies, but also result in 12% fewer biopsies in patients with prostate cancer, mostly with Gleason score <7 tumors. Genetically adjusted PSA was more predictive of aggressive prostate cancer (odds ratio (OR)=3.44, P=6.2×10-14; AUC=0.755) than unadjusted PSA (OR=3.31, P=1.1×10-12; AUC=0.738) in 106 cases and 23,667 controls. Compared to a prostate cancer PGS alone (AUC=0.712), including genetically adjusted PSA improved detection of aggressive disease (AUC=0.786, P=7.2×10-4). Our findings highlight the potential utility of incorporating PGS for personalized biomarkers in prostate cancer screening.
Competing Interest Statement
John S. Witte is a non-employee, cofounder of Avail Bio. Hans Lilja is named on a patent for intact PSA assays and a patent for a statistical method to detect prostate cancer that is licensed to and commercialized by OPKO Health. HL receives royalties from sales of the test and has stock in OPKO Health.
Funding Statement
The Precision PSA study is supported by funding from the National Institutes of Health (NIH) National Cancer Institute (NCI) under award number R01CA241410 (PI: JSW). Additionally, LK is supported by funding from National Cancer Institute (K99CA246076) and REG is supported by a Young Investigator Award from the Prostate Cancer Foundation. This work was supported by research grants from the NIH National Institute of General Medical Sciences (NIGMS) under award number R01GM130791 (PI: JDM). HL is supported in part by NIH/NCI by a Cancer Center Support Grant to Memorial Sloan Kettering Cancer Center [P30 CA008748], prostate cancer SPORE grant [P50-CA92629], Swedish Cancer Society (Cancerfonden 20 1354 PjF), and General Hospital in Malmo Foundation for Combating Cancer. This work was supported in part through the computational resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai. Research reported in this paper was supported by the Office of Research Infrastructure of the National Institutes of Health under award number S10OD026880 and NIH/NCI funding (R01CA175491, R01CA244948; PI: RJK). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The research was conducted with approved access to UK Biobank data under application number 14105 (PI: Witte). UK Biobank data are publicly available by request from https://www.ukbiobank.ac.uk. To maintain individuals' privacy, data on the GERA cohort are available by application to the Kaiser Permanente Research Bank (researchbank.kaiserpermanente.org). Informed consent was obtained from all study participants. UK Biobank received ethics approval from the Research Ethics Committee (REC reference: 11/NW/0382) in accordance with the UK Biobank Ethics and Governance Framework. The Kaiser Permanente Northern California Institutional Review Board and the University of California San Francisco Human Research Protection Program Committee on Human Research approved the GERA study. The institutional review board at the National Cancer Institute approved the PLCO study. The Vanderbilt Institutional Review Board approved the BioVU study. The Ethics Committee at Lund University approved the Malmo Diet & Cancer Study. The SELECT Coordinating Center institutional review board approved the SELECT study after its transition from a randomized control trial (clinicaltrials.gov NCT00006392) to an observational cohort. The PCPT was designed by investigators at the National Cancer Institute and SWOG (formerly the Southwest Oncology Group) and approved by institutional review boards at all sites.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* These authors jointly supervised this work Rebecca E. Graff, Department of Epidemiology and Biostatistics, Mission Hall: Global Health & Clinical Sciences Building 550 16th Street, 2nd Floor, Box #0560, San Francisco, CA 94158 Email: Rebecca.Graff{at}ucsf.edu, John S. Witte, Department of Epidemiology and Population Health Alway Building, Suite M121, 300 Pasteur Drive, Stanford, CA 94305, Email: jswitte{at}stanford.edu
Corrected p-values in abstract and author affiliations
Data Availability
UK Biobank data are publicly available by request from https://www.ukbiobank.ac.uk. To maintain individuals' privacy, data on the GERA cohort are available by application to the Kaiser Permanente Research Bank (researchbank.kaiserpermanente.org).
